Engineering the glioblastoma microenvironment using TLR7/8 agonist-complexed graphene oxide nanosheets
Source abstract
Abstract
Publisher of over 50 scientific journals across the life, physical, earth, and health sciences, both independently and in partnership with scientific societies including Cell, Neuron, Immunity, Current Biology, AJHG, and the Trends Journals.
Only a short abstract or summary was supplied by the source.
Source: openalex_inverted_index · Quality: short
Research context
OpenAlex topics: Graphene and Nanomaterials Applications · Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (85)
Show source-provided references
1. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma-a critical review
2. Glioblastoma multiforme: A review of its epidemiology and pathogenesis through clinical presentation and treatment
3. The 2021 WHO classification of tumors of the central nervous system: A summary10.1093/neuonc/noab106 ↗
4. Distinct regional ontogeny and activation of tumor associated macrophages in human glioblastoma10.1038/s41598-020-76657-3 ↗
5. Tumor-associated macrophages and anti-tumor therapies: complex links10.1007/s00018-016-2166-5 ↗
6. Tumor-associated macrophages as a paradigm of macrophage plasticity, diversity, and polarization: lessons and open questions10.1161/ATVBAHA.113.300168 ↗
7. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation10.1189/jlb.0609385 ↗
8. Alternative activation of macrophages10.1038/nri978 ↗
9. Blood monocyte-derived CD169+ macrophages contribute to antitumor immunity against glioblastoma10.1038/s41467-022-34001-5 ↗
10. The molecular profile of microglia under the influence of glioma10.1093/neuonc/nos116 ↗
11. The role of microglia and macrophages in glioma maintenance and progression10.1038/nn.4185 ↗
12. Role of inflammatory mediators, macrophages, and neutrophils in glioma maintenance and progression: Mechanistic understanding and potential therapeutic applications10.3390/cancers13164226 ↗
13. Anti-CD47 treatment stimulates phagocytosis of glioblastoma by M1 and M2 polarized macrophages and promotes M1 polarized macrophages in vivo
14. Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival10.18632/oncotarget.1291 ↗
15. TLR-mediated metabolic reprogramming in the tumor microenvironment: potential novel strategies for cancer immunotherapy10.1038/cmi.2018.4 ↗
16. Macrophages eat cancer cells using their own calreticulin as a guide: roles of TLR and Btk10.1073/pnas.1424907112 ↗
17. Small anti-viral compounds activate immune cells via the TLR7 MyD88–dependent signaling pathway10.1038/ni758 ↗
18. Topically applied resiquimod versus imiquimod as a potential adjuvant in melanoma treatment10.3390/pharmaceutics14102076 ↗
19. Development of immune memory to glial brain tumors after tumor regression induced by immunotherapeutic toll-like receptor 7/8 activation10.4161/onci.19068 ↗
20. Diclofenac inhibits lactate formation and efficiently counteracts local immune suppression in a murine glioma model10.1002/ijc.27712 ↗
21. TLR ligands in the local treatment of established intracerebral murine gliomas10.4049/jimmunol.181.10.6720 ↗
22. T cell-independent eradication of experimental glioma by intravenous TLR7/8-agonist-loaded nanoparticles10.1038/s41467-023-36321-6 ↗
23. Phase I study utilizing a novel antigen-presenting cell-targeted vaccine with Toll-like receptor stimulation to induce immunity to self-antigens in cancer patients10.1158/1078-0432.CCR-11-0891 ↗
24. Effective innate and adaptive antimelanoma immunity through localized TLR7/8 activation10.4049/jimmunol.1401160 ↗
25. TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy10.1038/s41551-018-0236-8 ↗
26. Intratumoral combination therapy with poly(I:C) and resiquimod synergistically triggers tumor-associated macrophages for effective systemic antitumoral immunity
27. Intracerebral injection of CpG oligonucleotide for patients with de novo glioblastoma-A phase II multicentric, randomised study10.1016/j.ejca.2016.12.003 ↗
28. CSF-1R inhibition alters macrophage polarization and blocks glioma progression10.1038/nm.3337 ↗
29. First in human phase I trial of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancer10.1158/1078-0432.CCR-07-1443 ↗
30. Toll-like receptor-targeted anti-tumor therapies: Advances and challenges10.3389/fimmu.2022.1049340 ↗
31. Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study10.1093/neuonc/nop047 ↗
32. Nanocarriers for the treatment of glioblastoma multiforme: Current state-of-the-art10.1016/j.jconrel.2016.02.026 ↗
33. Targeted regulation of blood-brain barrier for enhanced therapeutic efficiency of hypoxia-modifier nanoparticles and immune checkpoint blockade antibodies for glioblastoma10.1021/acsami.1c00347 ↗
34. High-density lipoprotein-mimicking nanodiscs for chemo-immunotherapy against glioblastoma multiforme
35. Genotype-targeted local therapy of glioma10.1073/pnas.1805751115 ↗
36. Enhancing antibody-dependent cellular phagocytosis by Re-education of tumor-associated macrophages with resiquimod-encapsulated liposomes10.1016/j.biomaterials.2020.120601 ↗
37. Development of Toll-like receptor agonist-loaded nanoparticles as precision immunotherapy for reprogramming tumor-associated macrophages10.1021/acsami.1c01453 ↗
38. A biomimetic polymer magnetic nanocarrier polarizing tumor-associated macrophages for potentiating immunotherapy10.1002/smll.202003543 ↗
39. Purified graphene oxide dispersions lack in vitro cytotoxicity and in vivo pathogenicity10.1002/adhm.201200248 ↗
40. Advanced review of graphene-based nanomaterials in drug delivery systems: Synthesis, modification, toxicity and application10.1016/j.msec.2017.03.196 ↗
41. Stable, concentrated, biocompatible, and defect-free graphene dispersions with positive charge10.1039/D0NR02689A ↗
42. First-in-human controlled inhalation of thin graphene oxide nanosheets to study acute cardiorespiratory responses10.1038/s41565-023-01572-3 ↗
43. The impact of graphene oxide sheet lateral dimensions on their pharmacokinetic and tissue distribution profiles in mice10.1016/j.jconrel.2021.08.028 ↗
44. Intracerebral injection of graphene oxide nanosheets mitigates microglial activation without inducing acute neurotoxicity: A pilot comparison to other nanomaterials10.1002/smll.202004029 ↗
45. Deep tissue translocation of graphene oxide sheets in human glioblastoma 3D spheroids and an orthotopic xenograft model10.1002/adtp.202000109 ↗
46. Graphene Oxide Nanoscale Platform Enhances the Anti-Cancer Properties of Bortezomib in Glioblastoma Models10.1002/adhm.202201968 ↗
47. In Situ Transforming RNA Nanovaccines from Polyethylenimine Functionalized Graphene Oxide Hydrogel for Durable Cancer Immunotherapy10.1021/acs.nanolett.0c05039 ↗
48. Simultaneous delivery of DNA vaccine and hydrophobic adjuvant using reducible polyethylenimine-functionalized graphene oxide for activation of dendritic cells10.1016/j.jiec.2019.08.038 ↗
49. Engineering of a graphene oxide-based two-dimensional platform for immune activation and modulation
50. Functionally-relevant morphological profiling: A tool to assess cellular heterogeneity10.1016/j.tibtech.2017.10.007 ↗
51. Classification of M1/M2-polarized human macrophages by label-free hyperspectral reflectance confocal microscopy and multivariate analysis10.1038/s41598-017-08121-8 ↗
52. Turning tumour cells into antigen presenting cells: The next step to improve cancer immunotherapy?10.1016/j.ejca.2016.09.010 ↗
53. Cancer-related inflammation10.1038/nature07205 ↗
54. Glioma grade is associated with the accumulation and activity of cells bearing M2 monocyte markers10.1158/1078-0432.CCR-12-1940 ↗
55. Tumor-associated macrophages and survival in classic Hodgkin’s lymphoma10.1056/NEJMoa0905680 ↗
56. Pharmacological targeting of the tumor–immune symbiosis in glioblastoma10.1016/j.tips.2022.04.002 ↗
57. Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages10.1038/nature21409 ↗
58. Graphene-based smart platforms for combined Cancer therapy10.1002/adma.201800662 ↗
59. Graphene and other 2D materials: a multidisciplinary analysis to uncover the hidden potential as cancer theranostics10.7150/thno.40068 ↗
60. Graphene and the immune system: a romance of many dimensions10.3389/fimmu.2017.00673 ↗
61. Microglia Polarization and Antiglioma Effects Fostered by Dual Cell Membrane-Coated Doxorubicin-Loaded Hexagonal Boron Nitride Nanoflakes10.1021/acsami.3c17097 ↗
62. The effects of extensive glomerular filtration of thin graphene oxide sheets on kidney physiology10.1021/acsnano.6b03358 ↗
63. Nose-to-brain translocation and cerebral biodegradation of thin graphene oxide nanosheets10.1016/j.xcrp.2020.100176 ↗
64. Splenic capture and In Vivo intracellular biodegradation of biological-grade graphene oxide sheets10.1021/acsnano.0c03438 ↗
65. Live imaging of label-free graphene oxide reveals critical factors causing oxidative-stress-mediated cellular responses10.1021/acsnano.7b07734 ↗
66. Size-dependent pulmonary impact of thin graphene oxide sheets in mice: toward safe-by-design10.1002/advs.201903200 ↗
67. Irreversible electroporation combined with checkpoint blockade and TLR7 stimulation induces antitumor immunity in a murine pancreatic cancer model10.1158/2326-6066.CIR-19-0101 ↗
68. The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer10.1038/s41467-019-12657-w ↗
69. T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity10.1038/s41467-017-01830-8 ↗
70. Systemic administration of the TLR7/8 agonist resiquimod (R848) to mice is associated with transient, in Vivo-detectable brain swelling10.3390/biology11020274 ↗
71. Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies10.1016/j.jhep.2007.02.025 ↗
72. Tissue distribution and urinary excretion of intravenously administered chemically functionalized graphene oxide sheets10.1039/C5SC00114E ↗
73. Intratumoral immunotherapy using platelet-cloaked nanoparticles enhances antitumor immunity in solid tumors10.1038/s41467-021-22311-z ↗
74. Dual immunostimulatory pathway agonism through a synthetic nanocarrier triggers robust anti-tumor immunity in murine glioblastoma10.1002/adma.202208782 ↗
75. T lymphocytes as dynamic regulators of glioma pathobiology10.1093/neuonc/noac055 ↗
76. Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 14310.1093/neuonc/nox208 ↗
77. Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial10.1001/jamaoncol.2020.1024 ↗
78. Making a cold tumor hot: The role of vaccines in the treatment of glioblastoma10.3389/fonc.2021.672508 ↗
79. Uncovering the mechanisms that regulate tumor-induced T-cell anergy10.4161/onci.22679 ↗
80. CD8+ T cell differentiation and dysfunction in cancer10.1038/s41577-021-00574-3 ↗
81. T-cell dysfunction in glioblastoma: applying a new framework10.1158/1078-0432.CCR-18-0047 ↗
82. Immunophenotyping of newly diagnosed and recurrent glioblastoma defines distinct Immune exhaustion profiles in peripheral and tumor-infiltrating lymphocytes10.1158/1078-0432.CCR-17-2617 ↗
83. T-cell exhaustion signatures vary with tumor type and are severe in glioblastoma10.1158/1078-0432.CCR-17-1846 ↗
84. Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies10.1186/s40425-019-0724-8 ↗
85. A blueprint for the synthesis and characterisation of thin graphene oxide with controlled lateral dimensions for biomedicine10.1088/2053-1583/aac05c ↗